Expert consensus on optimal management of liver-related adverse events during CDK4/6 inhibitor therapy.

Saved in:
Bibliographic Details
Title: Expert consensus on optimal management of liver-related adverse events during CDK4/6 inhibitor therapy.
Authors: Pernas S; Medical Oncology Department, Institut Catala d'Oncologia (ICO)-Institut de Recerca Biomèdica de Bellvitge (IDIBELL) L'Hospitalet, Barcelona, Spain., Forns X; Liver Unit, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain., Martínez-Sáez O; Medical Oncology Department, Hospital Clinic, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain.; Department of Medicine, University of Barcelona, Barcelona, Spain., Andrade R; Unidad de Gestión Clínica de Enfermedades Digestivas, Instituto de Investigación Biomédica de Málaga (IBIMA), Plataforma BIONAND, Hospital Universitario Virgen de La Victoria, Universidad de Málaga, Málaga, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, CIBERehd, Madrid, Spain., Amador A; Gastroenterology Department, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.; IDIBELL. Universitat de Barcelona, Barcelona, Spain., López-Miranda E; Medical Oncology Department Hospital, Universitario Ramón y Cajal, Madrid, Spain., Bermejo B; Medical Oncology, Hospital Clínico Universitario de Valencia, Biomedical Research Institute INCLIVA, Valencia, Spain.; Medicine Department, Universidad de Valencia, Valencia, Spain., Mateos B; Gastroenterology Department. Ramón, Cajal University Hospital, Madrid, Spain., Cejuela M; Medical Oncology Department, Hospital Virgen del Rocio (Seville, Spain), , Institute of Biomedicine of Seville (IBiS), Seville, Spain., Villanueva MJ; Medical Oncology. Medical Oncology Department, Complejo Hospitalario Universitario de Vigo, Galicia, Spain., Ozores PP; Medical Oncology Dpt. Breast and Gynecological Unit, Hospital Clínico Universitario de Santiago de Compostela, Galicia, Spain.; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Galicia, Spain., Riveiro-Barciela M; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.; Liver Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Instituto de Salud Carlos III (Spain), European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Madrid, Spain., Bellet M; Breast Cancer Unit, Oncology Department, Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. mbellet@vhio.net.
Source: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2026 May 10. Date of Electronic Publication: 2026 May 10.
Publication Type: Journal Article; Review
Journal Info: Publisher: Springer Italia Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1699-3055
DOI:10.1007/s12094-026-04369-7